Status:
COMPLETED
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Lead Sponsor:
Dana-Farber Cancer Institute
Conditions:
Waldenstrom's Macroglobulinemia
Eligibility:
All Genders
30-90 years
Phase:
NA
Brief Summary
The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodi...
Detailed Description
* A medical data collection survey sheet will be filled out by the patient or doctor with medical information pertaining to how the patient responded to rituximab and other monoclonal antibodies for u...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's macroglobulinemia
Exclusion
Key Trial Info
Start Date :
January 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2007
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00142155
Start Date
January 1 2002
End Date
March 1 2007
Last Update
June 27 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115